News

Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals – Jazz Pharmaceuticals (NASDAQ:JAZZ)



Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Jazz Pharmaceuticals JAZZ in the last three months.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 2 1 0 0
Last 30D 0 1 0 0 0
1M Ago 1 0 0 0 0
2M Ago 2 1 1 0 0
3M Ago 0 0 0 0 0

In the assessment of 12-month price targets, analysts unveil insights for Jazz Pharmaceuticals, presenting an average target of $189.33, a high estimate of $225.00, and a low estimate of $135.00. Experiencing a 4.7% decline, the current average is now lower than the previous average price target of $198.67.

Analyzing Analyst Ratings: A Detailed Breakdown

A comprehensive examination of how financial experts perceive Jazz Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Joel Beatty Baird Announces Outperform $160.00
Joon Lee Truist Securities Maintains Buy $200.00
Ami Fadia Needham Maintains Buy $225.00
Ashwani Verma UBS Lowers Neutral $135.00 $170.00
Gregory Renza RBC Capital Lowers Outperform $191.00 $200.00
Ami Fadia Needham Lowers Buy $225.00 $226.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they ‘Maintain’, ‘Raise’, or ‘Lower’ their stance, it signifies their reaction to recent developments related to Jazz Pharmaceuticals. This insight gives a snapshot of analysts’ perspectives on the current state of the company.
  • Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from ‘Outperform’ to ‘Underperform’. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.
  • Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Jazz Pharmaceuticals’s future value. Comparing current and prior targets offers insights into analysts’ evolving expectations.

Capture valuable insights into Jazz Pharmaceuticals’s market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Jazz Pharmaceuticals analyst ratings.

Unveiling the Story Behind Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Financial Insights: Jazz Pharmaceuticals

Market Capitalization Analysis: The company’s market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Jazz Pharmaceuticals’s remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 3.35%. This signifies a substantial increase in the company’s top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: The company’s net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.1%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): The company’s ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.19%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): The company’s ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.31%, the company showcases effective utilization of assets.

Debt Management: Jazz Pharmaceuticals’s debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.66, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish “analyst ratings” for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.



Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button